Search results for "Metabolic disease"

showing 10 items of 778 documents

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients

2015

Abstract Objective We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects. Methods The study population consisted of 40 reproductive-age women with PCOS, who underwent treatment with metformin during a 12-week period, and their corresponding matched controls (n = 44). We evaluated endocrinological parameters, adhesion molecules (vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1) and E-selectin) and proinflammatory cytokines (interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)) in serum. In addition, interactions between human umbili…

Adultmedicine.medical_specialtyTime FactorsAdolescentendocrine system diseasesEndotheliumType 2 diabetesProinflammatory cytokineYoung AdultInsulin resistanceInternal medicineCell AdhesionHuman Umbilical Vein Endothelial CellsLeukocytesmedicineHumansLeukocyte RollingEndothelium Leukocyte Metformin Mitochondria PCOS Type 2 diabetesCells CulturedCell adhesion moleculebusiness.industryEndothelial Cellsnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryCoculture TechniquesMetforminMetforminEndothelial stem cellTreatment Outcomemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2SpainCytokinesFemaleInflammation MediatorsCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersPolycystic Ovary Syndromemedicine.drugAtherosclerosis
researchProduct

Growth factor concentrations and their placental mRNA expression are modulated in gestational diabetes mellitus: possible interactions with macrosomia

2009

Abstract Background Gestational diabetes mellitus (GDM) is a form of diabetes that occurs during pregnancy. GDM is a well known risk factor for foetal overgrowth, termed macrosomia which is influenced by maternal hypergycemia and endocrine status through placental circulation. The study was undertaken to investigate the implication of growth factors and their receptors in GDM and macrosomia, and to discuss the role of the materno-foeto-placental axis in the in-utero regulation of foetal growth. Methods 30 women with GDM and their 30 macrosomic babies (4.75 ± 0.15 kg), and 30 healthy age-matched pregnant women and their 30 newborns (3.50 ± 0.10 kg) were recruited in the present study. Serum …

Adultmedicine.medical_specialtyTunisiaendocrine system diseasesOffspringPlacentalcsh:Gynecology and obstetricsFetal MacrosomiaReceptor Platelet-Derived Growth Factor betaGrowth factor receptorEpidermal growth factorPregnancyPlacentaDiabetes mellitusInternal medicineResearch articleObstetrics and GynaecologyFetal macrosomiamedicineHumansRNA MessengerInsulin-Like Growth Factor Ilcsh:RG1-991PregnancyEpidermal Growth Factorbusiness.industryInfant NewbornObstetrics and Gynecologynutritional and metabolic diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationGestational diabetesDiabetes Gestationalmedicine.anatomical_structureEndocrinologyInsulin-Like Growth Factor Binding Protein 3Case-Control StudiesGrowth HormoneIntercellular Signaling Peptides and ProteinsFemaleFibroblast Growth Factor 2businessBMC Pregnancy and Childbirth
researchProduct

Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance.

2011

Insulin resistance is a feature of polycystic ovary syndrome (PCOS) and is related to mitochondrial and endothelial function.We tested whether hyperandrogenic insulin-resistant women with PCOS, who have an increased risk of vascular disease, display impaired leukocyte-endothelium interactions, and mitochondrial dysfunction.This was a prospective controlled study conducted in an academic medical center.The study population consisted of 43 lean reproductive-age women with PCOS and 39 controls subjects.We evaluated anthropometric and metabolic parameters, adhesion molecules, and interactions between leukocytes and human umbilical vein endothelial cells. Mitochondrial function was studied by as…

Adultmedicine.medical_specialtyUmbilical VeinsAdolescentendocrine system diseasesNeutrophilsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryVascular Cell Adhesion Molecule-1Cell SeparationBiologymedicine.disease_causeBiochemistrychemistry.chemical_compoundYoung AdultEndocrinologyInsulin resistanceOxygen ConsumptionInternal medicineE-selectinmedicineLeukocytesHumanschemistry.chemical_classificationReactive oxygen speciesInterleukin-6Tumor Necrosis Factor-alphaInsulinBiochemistry (medical)Endothelial Cellsnutritional and metabolic diseasesGlutathionemedicine.diseasePolycystic ovaryGlutathionefemale genital diseases and pregnancy complicationsMitochondriaEndothelial stem cellOxidative StressEndocrinologychemistrybiology.proteinFemaleInsulin ResistanceE-SelectinReactive Oxygen SpeciesOxidative stressPolycystic Ovary Syndrome
researchProduct

Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of …

2013

Study question Is it possible to distinguish metabolically healthy polycystic ovary syndrome (MH-PCOS) from metabolically unhealthy PCOS (MU-PCOS) by simple diagnostic tools such as body mass index (BMI), waist/hip ratio (WHR), at-risk category suggested by Androgen Excess Society (AES) and visceral adiposity index (VAI)? Summary answer VAI could be an easy and useful tool in clinical practice and in population studies for assessment of MU-PCOS. What is known already VAI is a good indicator of insulin sensitivity and cardiometabolic risk in oligo-ovulatory women with PCOS. Study design, size, duration We conducted a cross-sectional study of 232 women with PCOS in a university hospital setti…

Adultmedicine.medical_specialtyWaistAdolescentPopulationSettore MED/13 - EndocrinologiaDiagnosis DifferentialInsulin resistanceRisk FactorsInternal medicinemedicinePCOSHumanseducationAdiposityeducation.field_of_studybusiness.industryRehabilitationnutritional and metabolic diseasesObstetrics and GynecologyOdds ratioGlucose Tolerance Testmedicine.diseasePolycystic ovaryConfidence intervalCross-Sectional StudiesPhenotypeReproductive MedicineFemaleMetabolic syndromeInsulin ResistancebusinessEnergy MetabolismBody mass indexPolycystic Ovary SyndromeHuman reproduction (Oxford, England)
researchProduct

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

2015

PURPOSE: Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders). METHODS: 22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose…

Adultmedicine.medical_specialtyendocrine system diseasesAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/13 - EndocrinologiaPrediabetic StateYoung AdultEndocrinologyInsulin resistanceInternal medicineHyperinsulinismmedicineHumansInsulinPrediabetesbusiness.industryPolycystic ovary syndrome (PCOS)InsulinHyperandrogenismnutritional and metabolic diseasesGlucose clamp techniquemedicine.diseasePolycystic ovaryEndocrinologypolycystic ovary syndromeGlucose Clamp TechniqueFemaleInsulin ResistancebusinessHyperinsulinismPolycystic Ovary SyndromeJournal of endocrinological investigation
researchProduct

Major gender difference in association of FTO gene variant among severely obese children with obesity and obesity related phenotypes.

2008

Recent studies have shown that SNPs in the FTO gene predispose to childhood and adult obesity. In this study, we examined the association between variants in FTO and KIAA1005, a gene that maps closely to FTO, and obesity, as well as obesity related traits among 450 well characterised severely obese children and 512 normal weight controls. FTO showed significant association with several obesity related traits while SNPs in KIAA1005 did not. When stratified by gender, the FTO variant rs9939609 showed association with obesity and BMI among girls (P = 0.006 and 0.004, respectively) but not among boys. Gender differences were also found in the associations of the FTO rs9939609 with obesity relat…

Adultmedicine.medical_specialtyendocrine system diseasesAdolescentmedicine.medical_treatmentBiophysicsAlpha-Ketoglutarate-Dependent Dioxygenase FTOSingle-nucleotide polymorphismBiochemistryFTO genePolymorphism Single NucleotideRisk AssessmentBody Mass IndexInsulin resistanceSex FactorsRisk FactorsInternal medicineDiabetes mellitusmedicinePrevalenceSNPHumansGenetic Predisposition to DiseaseObesitySex DistributionChildMolecular BiologySwedenbusiness.industryInsulinnutritional and metabolic diseasesGenetic VariationProteinspathological conditions signs and symptomsCell Biologymedicine.diseaseObesityEndocrinologyPhenotypeInsulin ResistancebusinessBody mass indexBiochemical and biophysical research communications
researchProduct

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes

2007

Background: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters. Methods: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS. Results: Serum DHEAS w…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAndrogen Excesschemistry.chemical_compoundEndocrinologyInternal medicinePrevalenceHumansInsulinMedicineTestosteroneTestosteronebusiness.industryCholesterolInsulinPolycystic ovary syndrome (PCOS)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePhenotypePolycystic ovaryPhenotypeEndocrinologychemistryAdrenal CortexAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents

2021

Abstract Aims To analyze therapeutic inertia in type 2 diabetes (T2D) subjects with suboptimal glycemic control and treated with ≥2 non-insulin antidiabetic agents in a primary care setting. Methods A retrospective study was conducted using electronic medical records from subjects with HbA1c ≥7.0% (≥53 mmol/mol). Therapeutic inertia was defined as the absence of treatment intensification despite suboptimal glycemic control where intensification should have been implemented (HbA1c ≥7.5% [≥58 mmol/mol]). Time to the first intensification with non-insulin antidiabetic agent or insulin and HbA1c values at the time of intensification were evaluated by competing risk analysis. Results 2652 adults…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentTreatment intensificationInsulins030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsRetrospective StudiesTherapeutic inertiaGlycemicGlycated Hemoglobinbusiness.industryMedical recordInsulinnutritional and metabolic diseasesRetrospective cohort studymedicine.diseaseDiabetes Mellitus Type 2businessJournal of Diabetes and its Complications
researchProduct